Mobile Health Technology for Personalized Tobacco Cessation Support in Laos (Project Support Laos): Protocol for a Randomized Controlled Trial
Clinical Snapshot
PICO Framework
| P — Population | Adult smokers recruited from two national hospitals in Lao PDR (Setthathirath Hospital in Vientiane and Champasak Hospital in Champasak Province) |
| I — Intervention | Automated treatment (AT) consisting of standard care plus fully automated smartphone-based treatment program with interactive and personalized proactive messages, images, or videos |
| C — Comparator | Standard care (SC) consisting of brief advice to quit smoking, self-help written materials, and 2-week supply of nicotine replacement therapy (transdermal patches) |
| O — Outcomes | Primary: biochemically confirmed self-reported 7-day point prevalence abstinence at 12 months post enrollment. Secondary: abstinence at 3 and 6 months post enrollment |
Bottom Line
This protocol describes a randomized controlled trial testing smartphone-delivered tobacco cessation support in Lao PDR. While the study addresses an important public health need in a low-resource setting, the protocol lacks crucial methodological details including randomization procedures, sample size calculations, and blinding strategies. The intervention shows promise for culturally adapted mHealth approaches in developing countries, but results are not yet available. For Australian clinicians, this study has limited direct applicability given differences in healthcare infrastructure, existing cessation services, and cultural context. The protocol's emphasis on biochemical confirmation of abstinence and 12-month follow-up represents good practice standards. However, the absence of cost-effectiveness analysis and limited consideration of potential harms reduces its immediate clinical utility. Australian practitioners should continue relying on established evidence-based cessation interventions while monitoring this study's eventual results for insights into mHealth approaches for specific populations.
Key Findings
P Value: Not reported - study in progress
Effect Size: Not reported - study in progress
Primary Outcome: Data collection ongoing, results not yet available
Nnt Or Sensitivity: Cannot be calculated - results pending
Confidence Interval: Not reported - study in progress
Clinical Application
Low feasibility for direct implementation in Australia without significant adaptation of content, delivery methods, and integration with existing smoking cessation services Limited relevance to Australian practice. PBS already subsidizes smoking cessation aids. RACGP guidelines recommend established interventions. TGA-approved cessation medications widely available. Quitline services already provide telephone support Limited applicability to Australian smokers due to different healthcare infrastructure, cultural context, and technology access patterns
Abstract
BACKGROUND: Tobacco use remains the leading cause of preventable morbidity and mortality in Lao People's Democratic Republic (Lao PDR). Despite the prevalence of cigarette smoking in Lao PDR (51% in men and 7% in women), no national tobacco treatment programs are available. Therefore, the development and evaluation of sustainable tobacco cessation interventions suitable for widespread adoption in Lao PDR are pressing public health needs. OBJECTIVE: This project aims to adapt our theoretically and empirically based mobile health (mHealth) technology to help people quit smoking cigarettes in Lao PDR. METHODS: Our mHealth approach includes a fully automated, interactive, personalized, smartphone-delivered intervention for behavioral treatment. This project includes 2 main phases. In the first phase, we use formative research methods to adapt our intervention content to the sociocultural context, language, and communication styles of Laotians. In the second phase, we conduct a randomized controlled trial to evaluate the efficacy of our mHealth intervention. In the trial, adult smokers are recruited through 2 national hospitals: Setthathirath Hospital in Vientiane and Champasak Hospital in Champasak Province. Participants (n=500) are randomized to either the standard care (SC; n=250) or automated treatment (AT; n=250) group. SC consists of brief advice to quit smoking delivered by research staff, self-help written materials, and a 2-week supply of nicotine replacement therapy (transdermal patches). AT consists of all SC components plus a fully automated smartphone-based treatment program that involves interactive and personalized proactive messages, images, or videos. The primary health outcome of the trial is biochemically confirmed self-reported 7-day point prevalence abstinence 12 months post study enrollment. Secondary outcomes include abstinence at 3 and 6 months post enrollment. RESULTS: This study was approved by the ethical review boards of the respective domestic and international institutions. Data collection for the formative phase occurred from January 2022 to May 2023, and data analyses are ongoing. Data collection for the trial phase is ongoing and is expected to be completed by the end of 2026. CONCLUSIONS: If the proposed project is successful, it has the potential to transform health care services for tobacco treatment throughout Lao PDR and, ultimately, to significantly reduce tobacco-induced morbidity and mortality in the country. The AT's potential for widespread adoption and sustainability is enhanced by the direct involvement of Lao governmental stakeholders at multiple national institutes. Furthermore, the US-Lao collaborative work and capacity-building activities in this project will contribute to creating a knowledge base for mHealth research applications and advancing mHealth research capacity in Lao PDR.
References
- 1.Bui, T. C., Xangsayarath, P., Keopraseuth, P., Phandouangsy, K., Keothongkou, K., Dittaphong, V., Moriasi, C., Doan, K. T., Kulkarni, S., Soulaphy, C., Xayavong, D., Sangxayalath, V., Sengdara, K., Businelle, M. S., Frank-Pearce, S. G., Vidrine, J. I., & Vidrine, D. J. (2026). Mobile Health Technology for Personalized Tobacco Cessation Support in Laos (Project Support Laos): Protocol for a Randomized Controlled Trial. JMIR Research Protocols. https://doi.org/10.2196/89916
Related Research
PloS one
Factors associated with resilience among parents of children with autism spectrum disorder: A systematic review
23 June 2026
Cancer
Alcohol consumers' receptivity to artificial intelligence-generated alcohol-cancer risk messages: An experimental study.
15 June 2026
Human vaccines & immunotherapeutics
Immunogenicity and safety of AS03-adjuvanted A/Astrakhan/3212/2020 (H5N8)-like influenza vaccine in adults: Phase 1/2, observer-blinded, randomized trial
14 June 2026
This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service